Practitioner report involving intravenous use of vitamin K1 prompts label review and revision.
Burgess
T M
TM
Veterinary Practitioners' Reporting Program, US Pharmacopeia, Rockville, MD 20852, USA.
Meyer
E K
EK
Bataller
N
N
D016907:Adverse Drug Reaction Reporting Systems; D000818:Animals; D000925:Anticoagulants / Q000506:poisoning*; D000933:Antifibrinolytic Agents / Q000008:administration & dosage / Q000009:adverse effects*; D004283:Dog Diseases / Q000139:chemically induced / Q000188:drug therapy; D004285:Dogs; D004342:Drug Hypersensitivity / Q000209:etiology / Q000662:veterinary*; D004348:Drug Labeling; D006801:Humans; D007275:Injections, Intravenous / Q000662:veterinary; D011041:Poisoning / Q000188:drug therapy / Q000662:veterinary; D012378:Rodenticides / Q000506:poisoning*; D014481:United States; D014486:United States Food and Drug Administration; D010837:Vitamin K 1 / Q000008:administration & dosage / Q000009:adverse effects*; D014859:Warfarin / Q000037:antagonists & inhibitors / Q000506:poisoning
D000925:Anticoagulants; D000933:Antifibrinolytic Agents; D012378:Rodenticides; D014859:Warfarin; D010837:Vitamin K 1